Please refer attached file

23rd June, 2026 Surveillance Department Surveillance Department BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Clarification on news item appearing on NDTV Profit captioned - "Piramal Pharma Share Price Spikes Over 10% — What Is Driving The Rally?" Dear Sir / Madam, We refer to the communication received from the Exchanges dated 23rd June, 2026 seeking clarification on the news article appearing in the https://www.ndtvprofit.com/markets/piramal- pharma-shares-surge-over-10-percent-following-multiple-global-regulatory-approvals- 11674176 dated 23rd June, 2026 captioned "Piramal Pharma Share Price Spikes Over 10% — What Is Driving The Rally?" In this regard, we wish to clarify that the referenced news article does not contain any material information or event requiring disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI Listing Regulations"). Further, all information furnished by the Company is already in the public domain and, as on date, there is no material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations that remains undisclosed by the Company to the stock exchanges. We further wish to clarify that the movement in the share price of the Company appears to be driven by market dynamics, and the Company is not aware of any specific reason or information that may have resulted in the observed price movement. Kindly take the above on record. Thank you. Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com